Verastem

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

Verastem, Inc. (VSTM) CEO Brian Stuglik on Q2 2019 Results - Earnings Call Transcript

Verastem (VSTM) delivered earnings and revenue surprises of 2.04% and 41.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Verastem (VSTM) Reports Q2 Loss, Tops Revenue Estimates

Verastem announced they out-licensed COPIKTRA to Sanofi Develop and Commercialize in emerging markets. Verastem will receive an upfront payment of $5M, plus milestones and royalties.

Verastem Licenses COPIKTRA To Sanofi Ahead Of Critical Q2 Earnings

Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

Verastem Up on Positive Data From Early-Stage Copiktra Study

Verastem Oncology presented COPIKTRA data showing response rates of 44% to 57%, including complete response rates of 15% to 22% in patients with relapsed or refractory peripheral T-cell lymphoma.

Verastem Shares Response Rate From COPIKTRA Data

Blueprint Medicines

Incyte

uniQure

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

Verastem recently reported an uninspiring earnings report that revealed a big miss on revenue. The share price was decimated in the subsequent trading day and has me contemplating my position.

Verastem: A Speculative Buy

Verastem, Inc. (VSTM) CEO Robert Forrester on Q1 2019 Results - Earnings Call Transcript

Verastem (VSTM) delivered earnings and revenue surprises of -10.87% and -41.16%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Verastem (VSTM) Reports Q1 Loss, Lags Revenue Estimates

VSTM has recently hit 52-week lows in the wake of relentless shorting since FDA approval of Copiktra in September 2018.

Verastem: Is The Short Thesis Short-Sighted?

Verastem is now a commercial stage biotechnology pharmaceutical company with one approved drug, Copiktra. Verastem's stock price has fallen since it received its FDA approval.

Verastem Cancer Therapy Should Get Traction, Raise Stock Price

Geron

Inovio Pharmaceuticals

These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.

3 Penny Stocks That Could Make You Rich -- or Regretful

Verastem's new oncology drug isn't setting the world on fire.

Why Verastem Stock Broke Down Today

News for Verastem Stock (VSTM)